2018 AANS Annual Scientific Meeting-Oncolytic Adenoviruses: Clinical Trials and the Delivery Problem

Oncolytic Adenoviruses: Clinical Trials and the Delivery Problem

Video Transcription

Video Summary

In this video, Dr. Fred Lange from the MD Anderson Cancer Center discusses oncolytic adenoviruses, clinical trials, and the delivery problem. He acknowledges Dr. Martuzzi as the father of oncolytic viral therapy and discusses the potential of oncolytic viruses as biological therapies. Dr. Lange explains the features of Delta-24, an adenovirus that is tumor-selective, replicates in tumor cells, and infects cells independent of the normal Coxsackie adenoreceptor. He describes a phase 1 clinical trial where the virus was injected directly into tumors, resulting in signs of efficacy and immune responses. Dr. Lange also talks about combining Delta-24 with checkpoint inhibitors to enhance the anti-tumor response, as well as the potential use of mesenchymal stem cells to deliver the virus throughout the tumor. He concludes by highlighting the potential of these biological agents in treating cancer.

Asset Caption

Frederick F. Lang Jr., MD, FAANS

Keywords

oncolytic adenoviruses

clinical trials

delivery problem

Delta-24 adenovirus

checkpoint inhibitors